Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in California
30 open options
- TRIALNANOT_YET_RECRUITING
Ultrasonic Debris Clearance to Promote Brain Resilience
Ultrasonic Debris Clearance · sham — 1 site
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNARECRUITING
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
Photobiomodulation — 1 site
- TRIALNARECRUITING
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
Symani Surgical System — 3 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
ABBV-1758 · Placebo for ABBV-1758 · ABBV-1758 — 12 sites
- TRIALPHASE1RECRUITING
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RB-ADSC — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
18F-OP-801 — 3 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE1RECRUITING
CogT pSOPT Intervention Study
pSOPT · MLA — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT · KarX-EC · KarXT + KarX-EC Arm Matching Placebo — 22 sites
- TRIALPHASE1 / PHASE2RECRUITING
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
PrimePro™/ PrimeMSK™ — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNANOT_YET_RECRUITING
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
Education — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
Gen0Bh Transcranial Focused Ultrasound System (Active) · Gen0Bh Transcranial Focused Ultrasound System (Sham) — 4 sites
- TRIALNAENROLLING_BY_INVITATION
Assessing and Improving the Durability of Compensatory Cognitive Training for Older Veterans
Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules · Treatment As Usual — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALPHASE2RECRUITING
Alzheimer's Tau Platform: Master Protocol
AADvac1 · Tau2 — 1 site
- TRIALNAENROLLING_BY_INVITATION
AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment
AI-Supported Cognitive Rehabilitation — 1 site
- TRIALNARECRUITING
BID WM Digital Intervention in Aging
Coherence · Worder — 1 site
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALNARECRUITING
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
Active tDCS and Cognitive Training Intervention · Sham tDCS and Cognitive Training Intervention — 2 sites
- TRIALNARECRUITING
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
California Cognitive Assessment Battery — 1 site
- TRIALNARECRUITING
Remotely-supervised Neuromodulation in PPA
Lexical Retrieval Cascade Treatment · Remotely Supervised Transcranial Direct Current Stimulation- Active · Remotely Supervised Transcranial Direct Current Stimulation - Sham — 2 sites
- TRIALPHASE1RECRUITING
A Study of LY3439539 in Participants With Alzheimer's Disease
LY3439539 — 8 sites
- TRIALPHASE3RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Masupirdine 50 mg · Masupirdine 100 mg · Placebo — 44 sites
- TRIALEARLY_PHASE1RECRUITING
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
18F-JSS20-183A PET · Brain MRI · Amyloid PET — 2 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.